Physician profile
David Benton
NPI 1336346501
$3,303.68
in general payments reported to CMS, 2019-2025
23 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.42 · 2020: $116 · 2021: $50.88 · 2022: $2,423 · 2023: $189 · 2024: $222 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590 · Education: $63.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.16 |
| Education | $63.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $2,302.80 | 2022 | |
| Abbvie INC. | $173.00 | 2024-2025 | |
| Boston Scientific Corporation | $152.38 | 2023-2025 | Axios, Accolade Sr |
| Pharmacyclics LLC, An Abbvie Company | $129.26 | 2021-2023 | Imbruvica |
| Pfizer INC. | $71.22 | 2019-2024 | |
| Daiichi Sankyo INC. | $55.78 | 2023-2024 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $44.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.00 | 2024 | Rybrevant |
| Allergan, INC. | $37.88 | 2020 | |
| Genentech USA, INC. | $37.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.62 | 2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $31.69 | 2025 | Lynozyfic |
| Novartis Pharmaceuticals Corporation | $28.27 | 2025 | |
| Dermira, INC. | $24.01 | 2020 | |
| Progenics Pharmaceuticals, INC. | $23.59 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.79 | 2024 | Xospata |
| Beone Medicines USA, INC. | $19.59 | 2025 | Tevimbra |
| Seagen INC. | $19.35 | 2020 | |
| Smith+Nephew, INC. | $15.28 | 2023 | Pico 14, Pico 7 |
| Celgene Corporation | $14.90 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.